RESEARCH MONOGRAPH · KDC-MN-315

Bromocriptine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

76/100

Old-guard D2 agonist with surprising metabolic biology people forget about

Bromocriptine is mostly remembered as the original Parkinson's-era ergot agonist and the prolactinoma standard of care, and both of those framings undersell it. Sandoz launched it in the early 70s, and for a long time it was the workhorse D2 agonist before the non-ergots came along and ate that market for safety reasons (fibrosis risk on chronic ergot exposure is real).

What people forget: the Cycloset story. The quick-release morning-dose formulation got FDA approval for type 2 diabetes in 2009 based on the Cincinnati group's work showing improvements in glycemic control and a striking cardiovascular outcomes signal in the safety trial. The mechanism is a centrally-mediated resetting of circadian sympathetic tone, downstream effects on hepatic glucose output, lipogenesis, and adipose insulin sensitivity. Pijl and Meier published nice review pieces on this. Honestly thats one of the more interesting central-to-peripheral metabolic stories in the literature and it gets almost no attention because the molecule is generic and unsexy.

Mechanism is well-mapped: high-affinity D2 partial agonist, alpha-1 antagonist at higher concentrations, some 5-HT2 activity, and the ergot scaffold gives it a polypharmacology profile thats messier than the non-ergot generation. Pharmacokinetics are workable: oral bioavailability ~6%, half-life around 5 hours for the standard form, much shorter for Cycloset.

What we like for research: it's been around forever, the receptor binding profile is mapped out in detail, and you can use it as a reference D2 agonist in basically any dopaminergic assay with confidence. It's also a useful tool for circadian-metabolic experiments given the Cycloset data. Sourcing is fine, mesylate salt is the standard form, USP-grade material is widely available, vendor variability is minimal.

What we dont like: it's a dirty receptor binder by modern standards. For clean D2 work you'd rather use a non-ergot like pramipexole or quinpirole. And the fibrosis risk on chronic ergot exposure makes it a poor candidate for any long-duration in vivo study where you care about cardiac valve histology.

Established workhorse with an underrated metabolic angle. Worth knowing the Cycloset literature even if you're not directly working on diabetes.

Evidence: 85
Mechanism: 80
Reliability: 80
Safety: 65
Sourcing: 85
Value: 78
Signal: 65
Staying power: 70

Plain-language summary Intrigue 58 / 100

Bromocriptine is a semi-synthetic ergot alkaloid (chemically descended from a fungus that grows on rye) that activates D2 dopamine receptors. It was the first dopamine agonist used for Parkinson disease and remains the standard treatment for prolactin-secreting pituitary tumors, where it shrinks the tumor and normalizes hormone levels. It also has off-label uses in type 2 diabetes (a quick-release morning formulation called Cycloset improves glucose control through hypothalamic dopamine signaling) and has been investigated for obesity. Long-term ergot exposure carries cardiac valve and lung scarring risk, which has shifted prescribing toward newer non-ergot alternatives like pramipexole. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Ergoline D2 dopamine receptor agonist

An ergoline-derived D2 receptor agonist; used in Parkinson disease, prolactinoma, and (off-label) for diabetes and obesity research.

Abstract

Bromocriptine (2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotaman-3',6',18-trione; CAS 25614-03-3; molecular formula C32H40BrN5O5; molecular weight 654.59) is a semi-synthetic ergoline derivative developed at Sandoz and approved by the FDA in 1978 (Parlodel) for Parkinson disease and hyperprolactinemia. The compound is a high-affinity D2 dopamine receptor agonist (Ki approximately 5 nM) with secondary D1, alpha-adrenergic, and serotonergic effects. The dopaminergic activity in pituitary lactotrophs suppresses prolactin secretion (the prolactinoma indication); the activity in basal ganglia provides modest symptomatic relief in Parkinson disease (largely supplanted by levodopa and non-ergot agonists). A formulation released in the morning (Cycloset, FDA approved 2009) is approved for type 2 diabetes; the rationale is reset of the circadian dopaminergic peak and consequent metabolic improvement. Plasma half-life is 4 to 6 hours; metabolism is hepatic via CYP3A4. Used as a reference D2 agonist with broad receptor profile.

Mechanism of action

Ergoline-derived D2 dopamine receptor agonist; secondary D1, alpha-adrenergic, serotonergic activity. Suppresses prolactin secretion; modest Parkinson disease activity.

Reported research dose ranges

Clinical 1.25 to 30 mg in the published literature (Parkinson, prolactinoma); 0.8 to 4.8 mg morning (Cycloset for diabetes).

References

Vermeulen RJ, et al. Bromocriptine for Parkinson disease. Cochrane Database Syst Rev 2003.
Cincotta AH, et al. Bromocriptine (ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996.
Webster J, et al. Bromocriptine for prolactinoma: long-term outcomes. Clin Endocrinol 1992.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-315

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Bromocriptine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs